KRAS and neoplasm: For this reason, the therapeutic effect is achieved on a tumor with poor therapeutic options and that is resistant to cetuximab or doxorubicin treatment as such.37 As a consequence, application of this antibody—when combined to ANANAS–could potentially be extended to a wider number of breast cancers, including the KRAS-mutated ones, as well as to other cancer types expressing EGFR, regardless from the “first line” efficacy of cetuximab alone.